LLY - Eli Lilly and Company

NYSE - NYSE Delayed Price. Currency in USD
114.61
-0.49 (-0.43%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close115.10
Open114.96
Bid0.00 x 1000
Ask114.42 x 3100
Day's Range114.05 - 115.92
52 Week Range101.36 - 132.13
Volume3,601,270
Avg. Volume3,177,120
Market Cap110.041B
Beta (3Y Monthly)0.16
PE Ratio (TTM)13.88
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.58 (2.24%)
Ex-Dividend Date2019-11-14
1y Target EstN/A
  • Alkermes Submits NDA to FDA for Schizophrenia & Bipolar I Drug
    Zacks

    Alkermes Submits NDA to FDA for Schizophrenia & Bipolar I Drug

    Alkermes (ALKS) submits NDA to the FDA seeking approval of ALKS 3831 for the treatment of schizophrenia and bipolar I disorder.

  • MarketWatch

    Eli Lilly to create 100 jobs in Indianapolis as it adds capacity to its technology center campus

    Eli Lilly & Co. said Wednesday that it will create 100 new jobs in Indianapolis as it invests $400 million in its manufacturing facilities at its Lilly Technology Center campus. The drug maker said its plans are a result of increased demand for its medicines and for the production of additional capacity for future medicines, and are helped by having more capital available as a result of tax reform. "These investments support our manufacturing capabilities in Indianapolis, including additional capacity and technology upgrades to our active ingredient, syringe filling, device assembly and packaging operations," said Myles O'Neill, president of manufacturing operations. "All of these projects support Lilly's investment in next generation manufacturing and feature high levels of automation, robotics, new technologies and advanced data analytics." The stock, which was still inactive in premarket trading, has slipped 0.5% year to date, while the SPDR Health Care Select Sector ETF has climbed 13.0% and the S&P 500 has advanced 24.5%.

  • Steven Cohen's Top 5 Buys in the 3rd Quarter
    GuruFocus.com

    Steven Cohen's Top 5 Buys in the 3rd Quarter

    Billionaire investor’s top buy is casino resort operator MGM Continue reading...

  • Drug Legislation Likely to Dry Up Biotech Funding
    GuruFocus.com

    Drug Legislation Likely to Dry Up Biotech Funding

    Industry executives claim the proposed law will inhibit the development of life-saving medications Continue reading...

  • Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates
    Zacks

    Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates

    Merck (MRK) gets approval in Europe for Ebola vaccine. Roche, Glaxo (GSK) & Pfizer (PFE) provide pipeline updates.

  • Livongo Bounces Back After Revenue Guidance Boost
    GuruFocus.com

    Livongo Bounces Back After Revenue Guidance Boost

    Analysts set average 12-month target more than 70% above current price Continue reading...

  • Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss
    Zacks

    Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss

    Celldex (CLDX) reports mixed third-quarter results. Its revenues fall on reduced collaboration and contract revenues.

  • FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes
    Zacks

    FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes

    Eli Lilly (LLY) gets an unfavorable FDA panel vote to expand the label of its type II diabetes medicine Jardiance (2.5 mg) for type I diabetes.

  • Reuters

    FDA panel votes against Lilly-Boehringer Ingelheim's diabetes drug

    Independent experts on an FDA advisory panel on Wednesday voted against the use of an already approved diabetes drug from Eli Lilly and Co and Boehringer Ingelheim as an add-on to insulin therapy in patients with type 1 diabetes. The drug, empagliflozin, was approved in 2014 in doses of 10 mg and 20 mg to help lower blood sugar levels in patients with type 2 diabetes and is marketed as Jardiance.

  • Supernus Pharmaceuticals seeks FDA approval for ADHD drug
    American City Business Journals

    Supernus Pharmaceuticals seeks FDA approval for ADHD drug

    The fate of a local company’s treatment for attention deficit hyperactivity disorder is now in regulators’ hands. Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) has submitted its application to the Food and Drug Administration to take its ADHD drug to market, the company announced Monday. Supernus has put the product candidate through a handful of phase 3 clinical trials, to study its ability to reduce ADHD symptoms.

  • 4 Biotech Stocks That Could Keep Beating Wall Street
    Zacks

    4 Biotech Stocks That Could Keep Beating Wall Street

    The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.

  • Eli Lilly Has the Base to Support a New Rally
    TheStreet.com

    Eli Lilly Has the Base to Support a New Rally

    Let's check out the charts and technical indicators to see if these two investment approaches are pointing in the same direction. In the daily bar chart of LLY, below, we can see that prices have moved sideways since the beginning of July with buyers coming in around $105 while rallies above $115 plus have failed so far. Trading volume has been featureless since April but the daily On-Balance-Volume (OBV) line has been flat/steady since April.

  • Aduro (ADRO) Q3 Loss Wider Than Expected, Revenues Rise Y/Y
    Zacks

    Aduro (ADRO) Q3 Loss Wider Than Expected, Revenues Rise Y/Y

    Aduro's (ADRO) loss misses estimates in Q3 while revenues almost match the mark.

  • Corcept (CORT) Earnings Beat in Q3, Korlym Boosts Sales
    Zacks

    Corcept (CORT) Earnings Beat in Q3, Korlym Boosts Sales

    Corcept (CORT) rides high on both earnings and revenue beat in the third quarter.

  • Nektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock Up
    Zacks

    Nektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock Up

    Nektar's (NKTR) reports encouraging third-quarter results. The company continues to progress with its pipeline candidates. However, the timeline for its pain drug NKTR-181's approval remains uncertain.

  • GuruFocus.com

    US Indexes Close Mostly Flat Wednesday

    S&P; 500 gains 0.07% and Dow Jones falls 0.01% Continue reading...

  • Radius (RDUS) Q3 Earnings Beat Estimates on Tymlos Strength
    Zacks

    Radius (RDUS) Q3 Earnings Beat Estimates on Tymlos Strength

    Radius (RDUS) reports a narrower-than-expected loss and beats sales estimates in the third quarter of 2019 as Tymlos gains traction.

  • Which Pharmaceutical Stocks Are Outperforming All Other Stocks?
    Investor's Business Daily

    Which Pharmaceutical Stocks Are Outperforming All Other Stocks?

    Pharmaceutical stocks rose a single-digit percentage in the first 10 months of 2019, well below their gain for 2018. Still, there are standout companies among the industry group.

  • Allergan (AGN) Meets Q3 Earnings Estimates, Ups '19 Sales View
    Zacks

    Allergan (AGN) Meets Q3 Earnings Estimates, Ups '19 Sales View

    Botox, Juveederm fillers, Vraylar drive Allergan's (AGN) third-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.

  • Value Biotech ETFs & Stocks to Buy Now
    Zacks

    Value Biotech ETFs & Stocks to Buy Now

    Biotech valuation looks attractive amid a volley of good news. Investors can tap these stocks and ETFs.

  • What's in the Cards for Teva (TEVA) This Earnings Season?
    Zacks

    What's in the Cards for Teva (TEVA) This Earnings Season?

    Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q3 sales

  • Weekly CEO Buys Highlight
    GuruFocus.com

    Weekly CEO Buys Highlight

    CEO buys this past week include OPKO Health, Eli Lilly and Co., Wesbanco, AngioDynamics and TherapeuticsMD Continue reading...

  • GuruFocus.com

    Top Insider Buys Highlight for the Week of Nov. 1

    The largest insider buys this week were in American Airlines, Eli Lilly, Keurig Dr Pepper and Ford Continue reading...

  • Barrons.com

    Eli Lilly CEO David Ricks and Other Insiders Are Buying the Slumping Stock

    Chairman and CEO David Ricks made his first open-market purchase of stock late in October. The drug giant’s shares are in the red for the year while the S&P 500 is up double digits.

  • InvestorPlace

    WeWork IPO was a Failure – These 2 IPO Stocks are Surging

    I always keep tabs on IPO stocks, as I'm a big believer in investing early, but I'll be the first to tell you that it's not always easy.If you're looking for large, long-term gains - and who isn't? - investing early is necessary. One example you probably know is Facebook (NASDAQ:FB). If you'd invested five years ago, you'd be richer today than if you'd just invested this year.But on the road to greatness, Facebook hit its share of roadblocks. In fact, the stock went absolutely nowhere for over a year after its IPO in 2012.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe market is full of stories like that. And IPO stocks don't always go on to do great things. Some of the most anticipated IPOs fizzle out before they even begin, as we recently saw with the whole WeWork debacle. * 7 Stocks to Buy in November In the space of just one month, the coworking office space company filed for an IPO, saw potential creditors flee once they got a look at its financials, yanked the IPO entirely, and ultimately fired its scandalous CEO, Adam Neumann. WeWork was once privately valued at $47 billion, but now that seems to have gone up in smoke.One big problem here is that once WeWork got into the spotlight, the hype - and the valuation - got out of control. I've seen it many times before, but sooner or later, the honeymoon ends and reality sets in. Put These Two IPO Stocks On Your Watch ListRight now, the best-performing IPO stocks are also the least talked-about, which is pretty telling. A couple stand out to me right now. They might not have a cool enough story to get on TV, but you'll definitely want to put them on your watch list all the same.InMode (NASDAQ:INMD) is a medical device company based in Israel. Specifically, its products are used in minimally invasive surgical and aesthetic procedures in the fields of dermatology, cellulite removal, and gynecology. It's a $1 billion company by market cap, was founded in 2008, and has been profitable for years. Financial buzz puts the sector InMode is going after, medical aesthetics, at $22.2 billion in five years.INMD stock is up 133% since its IPO this August. Even better, its sales are on a steady climb, too - from $53 million in 2017 to $187 million projected for 2020. That would be 253% sales growth in just three yearsThe other promising, under-the-radar IPO is NextCure (NASDAQ:NXTC). It's a clinical stage biotech focused on cancer treatments. The company is pretty small at a market cap of less than $600 million, but it has a deal with drug giant Eli Lilly (NYSE:LLY) that could result in up to $1.4 billion in milestone payments. The stock is up 30% since its IPO this May. Given the lucrative deal with Big Pharma, I wouldn't be surprised to see much better gains down the road.If you've never heard of either of these IPO stocks before, I wouldn't be surprised. They've been neglected by the media "hype machine"… and that's promising. It tells me that there's still a lot of potential for future gains - gains that these companies can earn the old fashioned way: by selling more product and delivering shareholder value, year after year.I'll be keeping an eye out for that. You should, too.Matthew McCall left Wall Street to actually help investors -- by getting them into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), and +1,044% in Tesla (TSLA), just to name a few. Click here to see what Matt has up his sleeve now. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Buy-and-Hold Stocks to Play Investing's Biggest Trends * 7 Stocks to Buy in November * 5 Strong Buy Stocks Under $5 With Massive Upside Potential The post WeWork IPO was a Failure a€“ These 2 IPO Stocks are Surging appeared first on InvestorPlace.